# info@crystallizationsummit.com

Category : Keynote Presentations

Dr. Bob Docherty, Pfizer

Dr. Robert Docherty did his degree and PhD. at Strathclyde University and joined ICI/Zeneca in 1988 where he worked on the solid-state structure and crystallization of dyes, pigments, biocides,...

Digitally Enabled Workflows: Accelerating the Molecule to Medicine Journey

By Dr. Bob Docherty, Pfizer The focus would be on solid form screen & selection, crystallization process development, pre-formulation evaluations, particle engineering and projecting the API attributes to drug...

Reducing or Managing Complexity- New realities with emerging chemical space for small molecule developability

By Dr. Ahmad Sheikh, AbbVie   While new chemical entities represent majority of the drugs approved in the last five years, the diversity and complexity of these molecules continue...

Control, is it achievable in amorphous or poorly crystalline peptide isolations?

By Dr. Jeremy M. Merritt, Eli Lilly and Co. Abstract: pending

RSS
Follow by Email
LinkedIn
Share